A New Breed Generic Pharma Company
Cosette Pharmaceuticals is a generic pharma company dedicated to providing unique, sustainable solutions to our customers, partners and patients. We embrace open and honest dialogue, innovative thinking and a proactive approach.
Our Company
Driven to anticipate and meet customer needs and
Cosette Pharmaceuticals is a generic pharma company dedicated to providing unique, sustainable solutions to our customers, partners and patients. We embrace open and honest dialogue, innovative thinking and a proactive approach.
Our Company
Driven to anticipate and meet customer needs and
Location: United States, New Jersey, Morristown
Investors 1
| Date | Name | Website |
| - | Avista Cap... | avistacap.... |
Mentions in press and media 11
| Date | Title | Description |
| 04.01.2024 | Cosette Pharmaceutical Acquires Vyleesi | Cosette Pharmaceutical, a Bridgewater, NJ-based specialty pharmaceutical company with a focus on women’s health and cardiovascular medicines, acquired Vyleesi® from Palatin Technologies, Inc. (NYSE: PTN), which includes 5 Orange Book listed... |
| 15.06.2023 | EY Announces Apurva Saraf, President and CEO of Cosette Pharmaceuticals as an Entrepreneur Of The Year® 2023 New Jersey Award Winner | BRIDGEWATER, N.J.–(BUSINESS WIRE)–Ernst & Young LLP (EY US) today announced that Apurva Saraf, President and CEO of Cosette Pharmaceuticals was named an Entrepreneur Of The Year® 2023 New Jersey Award winner. The Entrepreneur Of The Yea... |
| 12.06.2023 | Cosette Pharmaceuticals Acquires Intrarosa from Endoceutics | Cosette Pharmaceuticals, a Bridgewater, NJ-based specialty pharmaceutical company, acquired Intrarosa, a company focused on prescription drug providing both estrogen and androgen for the treatment of moderate-to-severe dyspareunia, from End... |
| 08.06.2023 | Cosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc. | Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product BRIDGEWATER, N.J.–(BUSINESS WIRE)–Cosette Pharmaceuticals, Inc. (“Cosette”), a US-based specialty pharmaceutical ... |
| 02.11.2022 | OmniAb Announces Completion of Spin-Off and Business Combination | Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq EMERYVILLE, Calif. (November 1, 2022) – OmniAb, Inc. (NASDAQ: OABI) today announced the co... |
| 20.01.2022 | Cosette Pharmaceuticals Acquires Rights to Eight Branded Products from Daiichi Sankyo | Transformational Transaction Diversifies Cosette’s Business to Accelerate Future Growth BRIDGEWATER, NJ – JANUARY 18, 2022: Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, announced today that it has clo... |
| 14.07.2020 | Cosette Pharmaceuticals Appoints Seasoned Industry Executive Apurva Saraf as President and Chief Executive Officer | Bridgewater, NJ, July 14, 2020 – Cosette Pharmaceuticals, Inc. (“Cosette” or the “Company”), a privately held specialty generic pharmaceutical company primarily focused on extended topical and suppository products, announced today the appoi... |
| 04.11.2019 | Cosette Pharmaceuticals Acquires G&W Labs Plant | Cosette Pharmaceuticals, Inc., a generic pharmaceutical company primarily focused on extended topical and suppository products, announced today that it has purchased G&W Laboratories’ finished dosage manufacturing plant located in Linco... |
| 04.11.2019 | Cosette Pharmaceuticals Acquires G&W Labs Plant | Cosette Pharmaceuticals, Inc., a generic pharmaceutical company primarily focused on extended topical and suppository products, announced today that it has purchased G&W Laboratories’ finished dosage manufacturing plant located in Linco... |
| - | Avista Capital Partners Announces Leadership Transition, New Partners and Promotions | Thompson Dean to Transition to Chairman; David Burgstahler to Become Sole Managing Partner Josh Tamaroff and Alex Yu named Partners as Avista continues to realize significant growth NEW YORK, Aug. 18, 2021 /PRNewswire/ — Avista Capital Pa... |
Show more